NYSEAMERICAN:RNN - Rexahn Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.57 -0.02 (-3.39 %)
(As of 02/18/2019 10:39 AM ET)
Previous Close$0.5870
Today's Range$0.5629 - $0.60
52-Week Range$0.55 - $2.38
Volume508,444 shs
Average Volume1.31 million shs
Market Capitalization$21.39 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.

Receive RNN News and Ratings via Email

Sign-up to receive the latest news and ratings for RNN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:RNN
Previous SymbolNYSEMKT:RNN
CUSIPN/A
Phone+1-240-2685300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees17
Market Cap$21.39 million
OptionableOptionable

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Frequently Asked Questions

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "RNN."

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) issued its quarterly earnings data on Monday, November, 5th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.00. View Rexahn Pharmaceuticals' Earnings History.

When is Rexahn Pharmaceuticals' next earnings date?

Rexahn Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Rexahn Pharmaceuticals.

What price target have analysts set for RNN?

4 Wall Street analysts have issued 1 year price objectives for Rexahn Pharmaceuticals' stock. Their forecasts range from $8.00 to $10.00. On average, they anticipate Rexahn Pharmaceuticals' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 1,478.9% from the stock's current price. View Analyst Price Targets for Rexahn Pharmaceuticals.

What is the consensus analysts' recommendation for Rexahn Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rexahn Pharmaceuticals in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rexahn Pharmaceuticals.

What are Wall Street analysts saying about Rexahn Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rexahn Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. " (1/25/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and price target of $17. The majority of contribution to our valuation comes from RX-3117, which represents 72% of our $17 price target. The remaining valuation comes from RX-5902 (Supinoxin) for triple negative breast cancer. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (1/15/2019)

Has Rexahn Pharmaceuticals been receiving favorable news coverage?

Media headlines about RNN stock have trended somewhat positive this week, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Rexahn Pharmaceuticals earned a coverage optimism score of 1.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.

Are investors shorting Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,257,406 shares, an increase of 49.5% from the January 15th total of 841,221 shares. Based on an average trading volume of 2,249,582 shares, the short-interest ratio is presently 0.6 days. Approximately 3.4% of the company's shares are sold short. View Rexahn Pharmaceuticals' Current Options Chain.

Who are some of Rexahn Pharmaceuticals' key competitors?

Who are Rexahn Pharmaceuticals' key executives?

Rexahn Pharmaceuticals' management team includes the folowing people:
  • Dr. Ely Benaim, Chief Medical Officer (Age 58)
  • Dr. Lisa Elizabeth Nolan, Chief Bus. Officer (Age 57)
  • Mr. Douglas J. Swirsky C.F.A., CPA, CPA, CFA, CEO, Pres, CFO, Corp. Sec. & Director (Age 50)
  • Dr. Madhukar H. Trivedi M.D., Consultant
  • Dr. Andrew Eisen M.D., VP of Translational Medicine

Who are Rexahn Pharmaceuticals' major shareholders?

Rexahn Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include CVI Holdings LLC (4.13%). Company insiders that own Rexahn Pharmaceuticals stock include Ben Gil Price, Chang Ho Ahn, Charles Beever, Douglas J Swirsky and Lisa Nolan. View Institutional Ownership Trends for Rexahn Pharmaceuticals.

Which major investors are buying Rexahn Pharmaceuticals stock?

RNN stock was purchased by a variety of institutional investors in the last quarter, including CVI Holdings LLC. Company insiders that have bought Rexahn Pharmaceuticals stock in the last two years include Ben Gil Price, Charles Beever, Douglas J Swirsky and Lisa Nolan. View Insider Buying and Selling for Rexahn Pharmaceuticals.

How do I buy shares of Rexahn Pharmaceuticals?

Shares of RNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rexahn Pharmaceuticals' stock price today?

One share of RNN stock can currently be purchased for approximately $0.57.

How big of a company is Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals has a market capitalization of $21.39 million. Rexahn Pharmaceuticals employs 17 workers across the globe.

What is Rexahn Pharmaceuticals' official website?

The official website for Rexahn Pharmaceuticals is https://rexahn.com/cms/.

How can I contact Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals' mailing address is 15245 Shady Grove Rd Ste 455, ROCKVILLE, MD 20850-7203, United States. The company can be reached via phone at +1-240-2685300.


MarketBeat Community Rating for Rexahn Pharmaceuticals (NYSEAMERICAN RNN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  284 (Vote Outperform)
Underperform Votes:  228 (Vote Underperform)
Total Votes:  512
MarketBeat's community ratings are surveys of what our community members think about Rexahn Pharmaceuticals and other stocks. Vote "Outperform" if you believe RNN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RNN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel